Skip to main content

Advertisement

SpringerLink
Log in

Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The aims of this study were to assess serum Fas, FasL, TRAIL, and Bcl-2 levels in patients with juvenile-onset systemic lupus erythematosus (JSLE) and to evaluate their relations with disease activity parameters and nephritis. Forty-eight JSLE patients, 33 juvenile idiopathic arthritis (JIA, inflammatory controls) patients and 40 healthy controls were enrolled. sFas, sFasL, sTRAIL, and sBcl-2 serum levels were measured by ELISA. Disease activity parameters included SLEDAI score, ESR, anti-dsDNA antibodies, C3, and C4 levels. Thirty-five JSLE patients had nephritis and 32 patients were classified as having active disease (SLEDAI ≥4). Statistical analysis methods included Mann-Whitney test and Spearman’s rank test. JSLE patients had significantly increased sFas serum levels compared with healthy controls (median 177.6 vs. 117.5 pg/mL; p = 0.0001), higher sTRAIL (median 484.6 vs 270.8 pg/mL; p = 0.02), and reduced sFasL (median 0.05 vs 0.3 ng/mL; p = 0.0002). The same results were observed for JSLE patients with active disease and for patients with nephritis. Additionally, sFas levels in JSLE patients directly correlated with SLEDAI score (r = 0.40; p = 0.009), and sTRAIL levels were increased in JSLE patients with neuropsychiatric disease compared with those without this involvement (median 667.9 vs. 216.2 pg/mL; p = 0.03). Otherwise, sBcl-2 levels of JSLE patients were similar to healthy controls. JIA patients had sFas, sFasL, sTRAIL, and sBcl-2 serum levels similar to JSLE patients and to healthy controls. In summary, this study characterized in JSLE a distinct profile from adult SLE that comprises increased sFas, sTRAIL, and reduced sFasL, notably in patients with active disease and with nephritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Choi J, Kim ST, Craft J (2012) The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol 24:651–657

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Carneiro-Sampaio M, Liphaus BL, Jesus AA, Silva CAA, Oliveira JB, Kiss MH (2008) Understanding systemic lupus erythematosus physiopathology in the light of primary immunodeficiencies. J Clin Immunol 28:S34–S41

    Article  PubMed  Google Scholar 

  3. Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58:556–562

    Article  PubMed  Google Scholar 

  4. Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J (2008) Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 17:371–375

    Article  CAS  PubMed  Google Scholar 

  5. Liphaus BL, Bittencourt Kiss MH (2010) The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus. Clinics 65:327–333

    Article  PubMed  PubMed Central  Google Scholar 

  6. Liphaus BL, Bittencourt Kiss MH, Carrasco S, Goldenstein-Schainberg C (2007) Increased Fas and Bcl-2 expression on peripheral mononuclear cells from patients with active juvenile-onset systemic lupus erythematosus. J Rheumatol 34:1580–1584

    PubMed  Google Scholar 

  7. Liphaus BL, Kiss MHB, Carrasco S, Goldenstein-Schainberg C (2006) Increased Fas and Bcl-2 expression on peripheral blood T and B lymphocytes from juvenile-onset systemic lupus erythematosus, but not from juvenile rheumatoid arthritis and juvenile dermatomyositis. Clin Develop Immunol 13:283–287

    Article  CAS  Google Scholar 

  8. Liphaus BL, Kiss MHB, Carrasco S, Goldenstein-Schainberg C (2013) Reduced expressions of Fas and Bcl-2 proteins in CD14+monocytes and normal CD14 soluble levels in juvenile systemic lupus erythematosus. Lupus 22:940–947

    Article  CAS  PubMed  Google Scholar 

  9. Al-Maini MH, Mountz JD, Al-Mohri HA et al (2000) Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus 9:132–139

    Article  CAS  PubMed  Google Scholar 

  10. Sahebari M, Hatef MR, Rezaieyazdi Z, Abbasi M, Abbasi B, Mahmoudi M (2010) Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran. Arch Iranian Med 13:135–142

    CAS  Google Scholar 

  11. Hao JH, Ye DQ, Zhang GQ et al (2006) Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese. Arch Dermatol Res 297:329–332

    Article  CAS  PubMed  Google Scholar 

  12. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40:1126–1129

    Article  CAS  PubMed  Google Scholar 

  13. Tinazzi E, Puccetti A, Gerli R et al (2009) Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. Int Immunol 21:237–243

    Article  CAS  PubMed  Google Scholar 

  14. Lub-de Hooge MN, de Vries EGE, de Jong S, Bijl M (2005) Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 64:854–858

    Article  CAS  PubMed  Google Scholar 

  15. Rus V, Zernetkina V, Puliaev R, Cudrici C, Mathai S, Via CS (2005) Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. Clin Immunol 117:48–56

    Article  CAS  PubMed  Google Scholar 

  16. Sahin M, Aydintug O, Tunc SE, Tutkak H, Naziroglu M (2007) Serum soluble Fas levels in patients with autoimmune rheumatic diseases. Clin Biochem 40:6–10

    Article  CAS  PubMed  Google Scholar 

  17. Turi MC, D’Urbano M, Celletti E, Alessandri C, Valesini G, Paganelli R (2009) Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age. Arch Gerontol Geriatrics 49:221–226

    Article  CAS  Google Scholar 

  18. Jodo S, Kobayashi S, Kayagaki N et al (1997) Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 107:89–95

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB (1995) Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38:1735–1737

    Article  CAS  PubMed  Google Scholar 

  20. Castellino G, Corallini F, Trotta F, Secchiero P (2007) Eleveted levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies. Lupus 16:479–482

    Article  CAS  PubMed  Google Scholar 

  21. Ezzat MHM, El-Gammasy TMA, Shaheen KYA, El-Mezdawi RAM, Youssef MSM (2013) Up regulation of serum tumor necrosis factor-related apoptosis inducing ligand in juvenile-onset systemic lupus erythematosus: relation with disease activity, antibodies to double-stranded DNA, nephritis and neutropenia. Int J Rheum Dis 16:310–318

    Article  CAS  PubMed  Google Scholar 

  22. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  CAS  PubMed  Google Scholar 

  23. Petty RE, Southwood TR, Baum J et al (1998) Revision of the proposed classification criteria for juvenile idipathic arthritis: Durban 1997. J Rheumatol 25:1991–1994

    CAS  PubMed  Google Scholar 

  24. Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291

    PubMed  Google Scholar 

  25. Falcini F, Azzari C, Gelli V et al (1999) Reduction of bcl-2 in T cells during immunosuppressive therapy in patients with severe juvenile onset systemic lupus erythematosus. Clin Immunol 93:59–64

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was partially supported by FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) grant no. 2008/58238-4. Authors thank all patients for their kind participation and Dr. Clovis A. Silva for enabling patients’ enrollment. All authors were involved in drafting or revising the manuscript, and approved final version.

Author information

Authors and Affiliations

  1. Laboratory of Medical Investigation (LIM-36), Instituto da Criança, Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Enéas de Carvalho Aguiar 647, 5° andar, LIM 36, Cerqueira Cesar, São Paulo, CEP 05403-900, Brazil

    Bernadete L. Liphaus, Patrícia Palmeira & Magda Carneiro-Sampaio

  2. Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

    Maria Helena B. Kiss

  3. Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

    Solange Carrasco & Claudia Goldenstein-Schainberg

Authors
  1. Bernadete L. Liphaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Helena B. Kiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Solange Carrasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrícia Palmeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claudia Goldenstein-Schainberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Magda Carneiro-Sampaio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernadete L. Liphaus.

Ethics declarations

Disclosures

None.

Electronic supplementary material

ESM 1

(DOC 151 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liphaus, B.L., Kiss, M.H.B., Carrasco, S. et al. Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus. Clin Rheumatol 36, 2847–2852 (2017). https://doi.org/10.1007/s10067-017-3615-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3615-8

Keywords

Search

Navigation